APPLICATIONS PUBLISHED 23 JUNE 2004
Published: 1-Dec-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Spraying methods for producing powder formulations
Boehringer Ingelheim Pharma 1429722*
Treating effect of excessive reacting oxygen species
Synzyme Technologies 1429723*
Dosage form containing a confectionery compsn
McNeil-PPC 1429724*
Ophthalmic dept formulations for periocular or subconjunctival administration
Novartis 1429725*
A method for preparing liposome formulations with a predefined release profile
Yissum Research Development Company of the Hebrew University of Jerusalem 1429726*
Apoptosis-mimicking synthetic entities and use thereof in medical treatment
Vasogen Ireland; Bolton, Antony; Mandel, Arkady 1429727*
Sustained release preparations
SRL Technologies 1429728*
Combination dosage form containing a cholesterol-lowering agent, an inhibitor of the renin-angiotensin, and aspirin
Longwood Pharmaceutical Research 1429729*
Opioid formulations having reduced potential for abuse
Penwest Pharmaceuticals 1429730*
Nanoparticulate insulin formulations
Elan Pharma International 1429731*
A core formulation
Kos Life Sciences 1429732*
Preparation of microparticles
Upperton 1429733*
Controlled release solid dispersions
Egalet 1429734*
Method and device for producing granulates that comprise at least one pharmaceutical active substance
Steffens, Klaus-Juergen 1429735*
Organoleptically acceptable intraorally disintegrating compsns
Pharmacia 1429736*
Modified release dosage forms
McNeil-PPC 1429737*
Modified release dosage forms
McNeil-PPC 1429738*
Polymer release system
Egalet 1429739*
Core formulation comprising troglitazone and a biguanide
Kos Life Sciences 1429740*
Process for coating solid particles
Dow Global Technologies 1429741*
Modified release dosage forms
McNeil-PPC 1429742*
Dosage forms having an inner core and outer shapes with different shapes
McNeil-PPC 1429743*
Morphine polymer release system
Egalet 1429744*
Composite dosage forms having an inlaid portion
McNeil-PPC 1429745*
Dosage forms having an inner core and outer shell
McNeil-PPC 1429746*
Core formulation comprising pioglitazone hydrochloride and a biguanide
Koos Life Sciences 1429747*
Solid compsns comprising ramipril
Sherman, Bernard Charles 1429748*
Preparation of submicron-sized nanoparticles via dispersion and solvent or liquid phase removal
Baxter International 1429749*
Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
Synorx 1429750*
Salicylic acid salts, methods for the production and use thereof as medicaments
Boehringer Ingelheim Pharma 1429751*
Neuroprotective treatment methods using selective INOS inhibitors
Pharmacia; Manning, Pamela; Connor, Jane 1429752*
Pharmaceutical compsn comprising gamma-butyrobetaine
Kalvinsh, Ivars; Veveris, Maris; Birmans, Anatolijs 1429753*
Combination of selective opioids with muscarine antagonists for treating urinary incontinence
Gruenenthal 1429754*
Use of vitamin E succinate and antiandrogen combination
University of Rochester 1429755*
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
Schering 1429756*
Crystalline forms of of fluvastatin sodium
Ciba Specialty Chemicals 1429757*
Photodynamic prophyrin antimicrobial agents
Frontier Scientific 1429758*
Compounds useful for treating hepatitis C virus
Bristol-Myers Squibb 1429759*
Novel combination
Bayer HealthCare 1429760*
Novel 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
Solvay Pharmaceuticals 1429761*
4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
Solvay Pharmaceuticals 1429762*
Novel ligands for the HISB10 ZN2+ sites of the R-state insulin hexamer
Novo Nordisk 14299763*
Compsns and methods for the treatment of cancer
Bristol-Myers Squibb 1429764*
